MARKET

ARDX

ARDX

Ardelyx
NASDAQ
4.760
+0.250
+5.54%
After Hours: 4.730 -0.03 -0.63% 19:56 12/01 EST
OPEN
4.500
PREV CLOSE
4.510
HIGH
4.775
LOW
4.470
VOLUME
5.00M
TURNOVER
0
52 WEEK HIGH
5.13
52 WEEK LOW
1.680
MARKET CAP
1.10B
P/E (TTM)
-38.2637
1D
5D
1M
3M
1Y
5Y
The Latest Analyst Ratings for Ardelyx
Ardelyx has an average price target of $9.0 with a high of $11.00 and a low of $7.00. 5 analysts have provided ratings for ardelyx over the past 3 months. According to 5 analyst offering 12-month price targets in the last 3 months, ardeleyx has been rated bullish.
Benzinga · 2d ago
Weekly Report: what happened at ARDX last week (1120-1124)?
Weekly Report · 6d ago
7 Penny Stocks You’ll Regret Not Buying Soon: November 2023
NASDAQ · 11/23 02:44
Weekly Report: what happened at ARDX last week (1113-1117)?
Weekly Report · 11/20 10:29
Validea Detailed Fundamental Analysis - ARDX
NASDAQ · 11/17 21:00
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
NASDAQ · 11/17 14:00
Ardelyx gets FDA orphan drug designation for pediatric Xphozah
Healthcare ardelyx gets fda orphan drug designation for pediatric xphozah. Fda has given orphan designation to the drug for the treatment of hyperphosphatemia in children. Last month, the fda approved x phozah for adults with chronic kidney disease on dialysis.
Seeking Alpha · 11/15 21:41
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Gamida Cell (GMDA) and Ardelyx (ARDX)
TipRanks · 11/15 12:11
More
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.